Bortezomib use and outcomes for the treatment of multiple myeloma

Loke Crystal; Mollee Peter; McPherson Ian; Walpole Euan; Yue Mimi; Mutsando Howard; Wong Phillip; Weston Helen; Tomlinson Ross; Hollingworth Samantha

首页> 外文期刊>Internal medicine journal >Bortezomib use and outcomes for the treatment of multiple myeloma

【24h】

Bortezomib use and outcomes for the treatment of multiple myeloma

机译：Bortezomib用于治疗多发性骨髓瘤的使用和结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The public subsidy in Australia of bortezomib (Velcade) for untreated non-transplant multiple myeloma patients was based on the VISTA trial.

机译：None

著录项

来源
《Internal medicine journal》 |2020年第9期|共8页
作者
Loke Crystal; Mollee Peter; McPherson Ian; Walpole Euan; Yue Mimi; Mutsando Howard; Wong Phillip; Weston Helen; Tomlinson Ross; Hollingworth Samantha;
展开▼
作者单位

Univ Queensland Sch Pharm 20 Cornwall St Woolloongabba Qld 4102 Australia;

Princess Alexandra Hosp Dept Canc Serv Brisbane Qld Australia;

Princess Alexandra Hosp Dept Canc Serv Brisbane Qld Australia;

Princess Alexandra Hosp Dept Canc Serv Brisbane Qld Australia;

Princess Alexandra Hosp Dept Canc Serv Brisbane Qld Australia;

Toowoomba Hosp Darling Downs Hosp &

Hlth Serv Toowoomba Qld Australia;

Toowoomba Hosp Darling Downs Hosp &

Hlth Serv Toowoomba Qld Australia;

Sunshine Coast Univ Hosp Canc Care Serv Reg Canc Care Sunshine Coast Qld Australia;

Sunshine Coast Univ Hosp Canc Care Serv Reg Canc Care Sunshine Coast Qld Australia;

Univ Queensland Sch Pharm 20 Cornwall St Woolloongabba Qld 4102 Australia;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内科学;
关键词
bortezomib; multiple myeloma; survival; first-line therapy;

机译：Bortezomib;多发性骨髓瘤;生存;一线治疗;

相似文献

外文文献
中文文献
专利

1. Determining the optimal time for bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplant in the treatment of multiple myeloma [J] . Junru Liu, Juan Li, Beihui Huang, 中国癌症研究（英文版） . 2013,第002期
2. Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment [J] . Guangzhong Yang, Wenming Chen, Yin Wu 中国癌症研究（英文版） . 2013,第002期
3. Efficacy and safety study of subcutaneous injection of bortezomib in the treatment of de novopatients with multiple myeloma [J] . 刘辉中国医学文摘：内科学分册（英文版） . 2013,第004期
4. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma [J] . ZHENG Dong, LI Juan, HUANG Bei-hui, 中华医学杂志（英文版） . 2012,第024期
5. Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database [J] . Jimenez-Zepeda Victor H., Venner Christopher, McCurdy Arleigh, British Journal of Haematology . 2021,第3期

机译：与含有硼替佐米的方案和Lenalidomide的现实世界结果加上地塞米松用于治疗移植型无骨髓瘤：来自加拿大骨髓瘤研究组数据库的多机构报告
6. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. [J] . Mateos MV, Oriol A, Martinez Lopez J, The lancet oncology . 2010,第10期

机译：对于未经治疗的多发性骨髓瘤老年患者，硼替佐米，美法仑和泼尼松与硼替佐米，沙利度胺和泼尼松作为诱导疗法，然后采用硼替佐米和沙利度胺与硼替佐米和泼尼松维持治疗：一项随机试验。
7. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. [J] . Antonio Palumbo, Sara Bringhen, Alessandra Larocca, Journal of Clinical Oncology . 2014,第7期

机译：Bortezomib-Melphalan-prednisone-renalomide随后与Bortezomib-Melphalan-Prednisone进行硼替佐米胺维持，用于初始治疗多发性骨髓瘤：更新后续和提高存活。
8. Proteomic alterations caused by treatment with Bortezomib, Doxorubicin, and Dexamethasone in Myeloma [C] . Dominik Dytfeld, Vadiraja B. Bhat, Malathi Hari, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2009

机译：用髓质族，多柔比星和地塞米松治疗引起的蛋白质组学改变
9. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
10. Protein Kinase D 1 Predicts Poor Treatment Response and Unfavorable Survival of Bortezomib-Based Treatment and Its Knockdown Enhances Drug Sensitivity to Bortezomib in Multiple Myeloma [O] . Xuesong Li, Ying Yang, Xue Yi 2020

机译：蛋白激酶D1预测基于Bortezomib的治疗的差治疗反应和不利存活其敲低增强了对多发性骨髓瘤中硼卓罗米布的药物敏感性
11. Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment [O] . Su-Hee Cho, Ho-jin Shin, Ki Sun Jung, 2019

机译：剂量调节有助于获得多发性骨髓瘤患者的更好的蛋白质，Melphalan和泼尼松（VMP）治疗
12. Treatment of Multiple Myeloma with VLA4-Targeted Nanoparticles Delivering Novel c-MYC Inhibitor Prodrug. [R] . Tomasson, M. 2012

机译：用VLa4靶向纳米粒子治疗多发性骨髓瘤，提供新型c-mYC抑制剂前体药物。

Bortezomib use and outcomes for the treatment of multiple myeloma

摘要

著录项

相似文献

相关主题

期刊订阅